Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 9/20 | 0.40 |
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA9 | Q16790 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536869 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12CA2CA9CYP1A2 | |
| SCHEMBL5532386 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP1A2IKBKBKDM4EHSD17B10 | |
| SCHEMBL10185342 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP1A2IKBKBKDM4EHSD17B10 | |
| SCHEMBL2406658 | 0.78 | CA12 (0.48) | SMN1; SMN2CA12CA2CA9CA1 | |
| SCHEMBL8992099 | 0.76 | DGAT1 (0.45) | CA12CA2CA9CA1KDM4E | |
| SCHEMBL27897265 | 0.76 | CA12 (0.39) | SMN1; SMN2CA12CA2CA9CA1 | |
| SCHEMBL14734376 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP1A2KDM4EHSD17B10NPSR1 | |
| SCHEMBL18053236 | 0.74 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP1A2IKBKB | |
| SCHEMBL14734389 | 0.72 | KDM4E (0.38) | SMN1; SMN2CYP1A2KDM4ENPSR1MEN1 | |
| SCHEMBL9822756 | 0.72 | KDM4E (0.43) | SMN1; SMN2KDM4EHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703729-B2 | Pyrazine derivative, and preparation method and medical use thereof | GUANGZHOU MAGPIE PHARMACEUTICALS CO LTD (CN) | 2020-07-07 | — | — | US | disclosed |
| CN-106118882-B | A kind of preparation method of the Mei Lade essence of the cigarette based on discarded offal | 郑州大学 | 2019-10-11 | — | — | CN | disclosed |
| US-20190276413-A1 | Pyrazine derivative, and preparation method and medical use thereof | GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-8158630-B2 | Application of 2,5 -dihydroxymethyl-3,6-dimethyl pyrazine and its derivates in pharmacy | Nanjing University of Chinese Medicine (CN) | 2012-04-17 | — | — | US | disclosed |
| US-20110195972-A1 | APPLICATION OF 2,5 -DIHYDROXYMETHYL -3,6 - DIMETHYL PYRAZINE AND ITS DERIVATES IN PHARMACY | Nanjing University of Chinese Medicine (CN) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276413-A1 | Pyrazine derivative, and preparation method and medical use thereof | RYR2, RYR1, ORAI1 | SMN1; SMN2 1062/4885CA12 4168/4885CA2 396/4885 |
| US-10703729-B2 | Pyrazine derivative, and preparation method and medical use thereof | RYR2, RYR1, ORAI1 | SMN1; SMN2 1062/4885CA12 4168/4885CA2 396/4885 |
| US-20110195972-A1 | APPLICATION OF 2,5 -DIHYDROXYMETHYL -3,6 - DIMETHYL PYRAZINE AND ITS DERIVATES IN PHARMACY | QDPR, DPP7, DPP3 | SMN1; SMN2 4254/4885CA12 3749/4885CA2 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.